The role of the c-Met pathway in lung cancer and the potential for targeted therapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Therapeutic Advances in Medical Oncology

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1758834011408636PMID 21904579PMCID PMC3150066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies

  2011cited by this paper
• Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism*

  2010cited by this paper
• CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases

  2010cited by this paper
• Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.

  2010cited by this paper
• MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.

  2010cited by this paper
• HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.

  2010cited by this paper
• Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• An Orally Available Small-Molecule Inhibitor of c-Met,PF-2341066,Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

  2010cited by this paper
• Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.

  2009cited by this paper
• PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription

  2009cited by this paper
• Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

  2009cited by this paper
• The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

  2009cited by this paper
• Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.

  2008cited by this paper
• Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer

  2008cited by this paper
• Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications

  2008cited by this paper
• First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors

  2008cited by this paper
• Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

  2008cited by this paper
• 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.

  2008cited by this paper
• Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

  2007cited by this paper
• Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose

  2007cited by this paper
• High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

  2007cited by this paper
• Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative.

  2007cited by this paper
• MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.

  2007cited by this paper
• A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

  2007cited by this paper
• Flt3-dependent transformation by inactivating c-Cbl mutations in AML.

  2007cited by this paper
• Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.

  2007cited by this paper
• c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma

  2007cited by this paper
• An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

  2007cited by this paper
• AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Identification of a novel germline MET mutation in dogs.

  2006cited by this paper
• MET overexpression turns human primary osteoblasts into osteosarcomas.

  2006cited by this paper
• Structural basis of hepatocyte growth factor/scatter factor and MET signalling.

  2006cited by this paper
• Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.

  2006cited by this paper
• A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo

  2006cited by this paper
• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  2006cited by this paper
• Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

  2006cited by this paper
• Met/Hepatocyte Growth Factor Receptor Ubiquitination Suppresses Transformation and Is Required for Hrs Phosphorylation

  2005cited by this paper
• Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung

  2005cited by this paper
• Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.

  2005cited by this paper
• Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis

  2005cited by this paper
• Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.

  2005cited by this paper
• A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

  2005cited by this paper
• The Sema domain of Met is necessary for receptor dimerization and activation.

  2004cited by this paper
• Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor

  2004cited by this paper
• Divergent functions of murine Pax3 and Pax7 in limb muscle development.

  2004cited by this paper
• Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias

  2004cited by this paper
• Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

  2003cited by this paper
• c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

  2003cited by this paper
• Endosomal dynamics of Met determine signaling output.

  2003cited by this paper
• A role for common fragile site induction in amplification of human oncogenes.

  2002cited by this paper
• [Molecular abnormalities in lung cancer].

  2002cited by this paper
• Distinct recruitment and function of Gab1 and Gab2 in Met receptor-mediated epithelial morphogenesis.

  2002cited by this paper
• Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer.

  2002cited by this paper
• Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model.

  2002cited by this paper
• Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

  2002cited by this paper
• Down-regulation of MET, the receptor for hepatocyte growth factor

  2001cited by this paper
• Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice

  2001cited by this paper
• Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development

  2001cited by this paper
• Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.

  2001cited by this paper
• A novel germ line juxtamembrane Met mutation in human gastric cancer

  2000cited by this paper
• Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization

  1999cited by this paper
• Hepatocyte growth factor, a versatile signal for developing neurons

  1999cited by this paper
• Novel mutations of the MET proto-oncogene in papillary renal carcinomas

  1999cited by this paper
• Molecular abnormalities in lung cancer.

  1998cited by this paper
• The mutationally activated Met receptor mediates motility and metastasis.

  1998cited by this paper
• The clinical significance of hepatocyte growth factor for non-small cell lung cancer.

  1998cited by this paper
• Met and hepatocyte growth factor/scatter factor expression in human gliomas.

  1997cited by this paper
• Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.

  1997cited by this paper
• Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

  1997cited by this paper
• Association of the Multisubstrate Docking Protein Gab1 with the Hepatocyte Growth Factor Receptor Requires a Functional Grb2 Binding Site Involving Tyrosine 1356*

  1997cited by this paper
• Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential

  1997cited by this paper
• Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

  1997cited by this paper
• Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas.

  1996cited by this paper
• Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.

  1996cited by this paper
• Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance

  1996cited by this paper
• An 11-Amino Acid Sequence from c-met Initiates Epithelial Chemotaxis via Phosphatidylinositol 3-Kinase and Phospholipase C (*)

  1996cited by this paper
• Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells.

  1996cited by this paper
• Pax3 modulates expression of the c-Met receptor during limb muscle development.

  1996cited by this paper
• Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis

  1996cited by this paper
• Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells.

  1995cited by this paper
• Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

  1995cited by this paper
• Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor

  1995cited by this paper
• The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit.

  1995cited by this paper
• Scatter factor/hepatocyte growth factor is essential for liver development

  1995cited by this paper
• Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).

  1994cited by this paper
• Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.

  1994cited by this paper
• Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).

  1994cited by this paper
• Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells.

  1994cited by this paper
• Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.

  1994cited by this paper
• Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase.

  1994cited by this paper
• A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.

  1994cited by this paper
• Scatter factor induces blood vessel formation in vivo.

  1993cited by this paper
• Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase

  1993cited by this paper
• The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor.

  1993cited by this paper
• Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development

  1993cited by this paper
• A novel putative receptor protein tyrosine kinase of the met family.

  1993cited by this paper

• Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances

  2026cites this paper
• Exploring AI tools and multi-omics for precision medicine in lung cancer therapy.

  2025cites this paper
• Computational investigation of hepatocyte growth factor receptor-ligand interactions for the identification of novel therapeutic inhibitors

  2025cites this paper
• Molecular Pathway Modulation and Nanotechnology-Based Therapeutic Strategies for Shikonin.

  2025cites this paper
• Therapeutic advances of targeting receptor tyrosine kinases in cancer

  2024cites this paper
• Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies

  2024cites this paper
• Unveiling LGR5: Prostate cancer's hidden stem cell and treatment target.

  2024cites this paper
• Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy.

  2024cites this paper
• Anticancer Potential of Natural Chalcones: In Vitro and In Vivo Evidence

  2023cites this paper
• N‐glycosylation regulates MET processing and signaling

  2022cites this paper
• Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer

  2022influential citation
• Dual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives

  2022cites this paper
• Preclinical study of a biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC.

  2022cites this paper
• Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing

  2022cites this paper
• An attention mechanism-based LSTM network for cancer kinase activity prediction

  2022cites this paper
• Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

  2022cites this paper
• Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies

  2021cites this paper
• New Scope of Targeted Therapies in Lung Carcinoma.

  2021cites this paper
• Pro-Oncogenic c-Met/EGFR, Biomarker Signatures of the Tumor Microenvironment are Clinical and Therapy Response Prognosticators in Colorectal Cancer, and Therapeutic Targets of 3-Phenyl-2H-benzo[e][1,3]-Oxazine-2,4(3H)-Dione Derivatives

  2021cites this paper
• MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer

  2021cites this paper
• Analysis of the Protein–Protein Interaction Network Identifying c-Met as a Target of Gigantol in the Suppression of Lung Cancer Metastasis

  2021cites this paper
• Crizotinib inhibits activation of MET pathway caused by MET extracellular SEMA domain duplication.

  2020cites this paper
• Single-domain antibodies for radio nuclear imaging and therapy of esophageal squamous cell carcinoma: a narrative review

  2020cites this paper
• Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target

  2020cites this paper
• Profils moléculaires des cancers bronchiques non à petites cellules à la Réunion

  2020cites this paper
• Preclinical Evaluation Of Curcumin And Its Meriva Formulation For Non-Small Cell Lung Cancer Chemoprevention

  2019cites this paper
• Incidence and risk of fatigue in cancer patients treated with MET inhibitors

  2019cites this paper
• The Role of KRAS in Mechanosensing in Non-Small Cell Lung Cancer

  2019cites this paper
• Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

  2019cites this paper
• MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population

  2019cites this paper
• First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

  2019cites this paper
• Lung Cancer Receptors and Targeting Strategies

  2019cites this paper
• Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.

  2019cites this paper
• Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase

  2019cites this paper
• Non small cell lung cancer with targetable driver alterations: Imaging perspective

  2019cites this paper
• Impaired ligand‐dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer

  2019cites this paper
• MET and RON Receptor Tyrosine Kinases as Therapeutic Antibody Targets for Cancer

  2018cites this paper
• Classification histomoléculaire des cancers pulmonaires

  2018cites this paper
• Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.

  2018cites this paper
• Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients

  2018cites this paper
• Receptor Tyrosine Kinase-Targeted Cancer Therapy

  2018cites this paper
• Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.

  2018cites this paper
• c-MET in Head and Neck Squamous Cell Carcinoma

  2018cites this paper
• The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer

  2017cites this paper
• Altérations moléculaires anciennes et émergentes : quand les rechercher ?

  2017cites this paper
• The Translational Applications of Using Oxadiazole-Derived Small-Molecule Agents to Induce Protein Degradation Pathways

  2017cites this paper
• Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy

  2017cites this paper
• Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

  2017cites this paper
• Use of iTRAQ to discover serum proteins associated with acquired EGFR-TKIs resistance in patients with advanced lung adenocarcinoma

  2017cites this paper
• Next‐generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy

  2017cites this paper
• [Cabozantinib: Mechanism of action, efficacy and indications].

  2017influential citation
• The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer

  2017cites this paper
• Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions

  2017cites this paper
• Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor‐mutant lung cancer

  2017cites this paper
• Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer

  2017cites this paper
• Functional characterisation of SPO11 in human cancer cells

  2017cites this paper
• Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells

  2017cites this paper
• New oncogenes drivers in lung cancer—new therapeutic targets

  2016cites this paper
• MOLECULAR PLAYERS OF LUNG CARCINOMA

  2016cites this paper
• Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues

  2016cites this paper
• Paired Box 5 (PAX5) Expression in Poorly Differentiated Neuroendocrine Carcinoma of the Gastrointestinal and Pancreatobiliary Tract: Diagnostic and Potentially Therapeutic Implications

  2016cites this paper
• Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays

  2016cites this paper
• Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

  2016cites this paper
• Simultaneous inhibition of EGFR and MET receptors with phytochemical conjugated magnetic nanocarriers: in silico and in vitro study

  2016cites this paper
• Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology

  2016cites this paper
• Anticorps bispécifiques pour une plus grande sélectivité et une meilleure inhibition des tumeurs, et utilisations associées

  2016cites this paper
• Effective Combined Treatment with Aqueous Extract of Taxuschinensis var.mairei (AETC) and Gefitinib in Inhibiting Non-SmallCell Lung Cancer PC9, PC9/R Cell Lines In Vitro and In Vivo

  2016cites this paper
• Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation

  2016cites this paper
• The Quorum Sensing Peptides PhrG, CSP and EDF Promote Angiogenesis and Invasion of Breast Cancer Cells In Vitro

  2015cites this paper
• Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer

  2015cites this paper
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

  2015cites this paper
• Antitumor activity of phenanthroindolizidine alkaloids is associated with negative regulation of Met endosomal signaling in renal cancer cells.

  2015cites this paper
• Papillary renal cell carcinoma: A review of the current therapeutic landscape.

  2015cites this paper
• Role of c-mesenchymal–epithelial transition pathway in gastric cancer

  2015cites this paper
• Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification

  2015cites this paper
• The Evolution of Therapies in Non-Small Cell Lung Cancer

  2015cites this paper
• Anticorps anti-met et compositions associées

  2015cites this paper
• Démembrement des adénocarcinomes bronchopulmonaires : le point de vue du pathologiste

  2015cites this paper
• Cancer Therapy: Preclinical LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

  2014cites this paper
• LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

  2014cites this paper
• EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

  2014cites this paper
• Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.

  2014cites this paper
• Cancer Therapy : Preclinical LY 2875358 , a Neutralizing and Internalizing Anti-MET Bivalent Antibody , Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

  2014cites this paper
• Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

  2014cites this paper
• Molecular pathways and therapeutic targets in lung cancer

  2014cites this paper
• Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

  2014cites this paper
• Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.

  2014cites this paper
• Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt Signaling in Hepatocyte Growth Factor (HGF)-mediated Lamellipodia Formation, Reactive Oxygen Species (ROS) Generation, and Motility of Lung Endothelial Cells*

  2014cites this paper
• Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients

  2014cites this paper
• FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells.

  2014cites this paper
• EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer

  2014cites this paper
• The Role of HGF/c-MET in Head and Neck Squamous Cell Carcinoma

  2014cites this paper
• Hepatocyte growth factor regulates myogenesis of mouse and human skeletal myoblasts.

  2014cites this paper
• Small Cell Lung Cancer - Inhibitor LY2801653 in Non Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule

  2014cites this paper
• Emerging combination therapies to overcome resistance in EGFR-driven tumors

  2014cites this paper
• Targeted next‐generation sequencing and non‐coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes

  2014cites this paper
• HGFasaCirculatingBiomarkerofOnartuzumabTreatmentin Patients with Advanced Solid Tumors

  2013cites this paper
• ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines

  2013cites this paper
• Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib

  2013cites this paper
• Companion Diagnostics & Cancer Biomarkers HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors

  2013cites this paper